JRT39 / Jalon Therap - LARVOL DELTA

AAC-11 survival pathways as therapeutic target in cancer: AAC-11 leucine-zipper domain derived peptides exert potent antitumor effects and exhibit favorable stability, pharmacokinetic and toxicology profiles (AACR 2023) - "Combined, our preclinical data confirm that interfering with AAC-11-related survival pathways is a promising novel anticancer strategy and support the development of JRT39 for the treatment of cancer."

PK/PD data • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Acute Promyelocytic Leukemia • Cutaneous T-cell Lymphoma • Hematological Malignancies • Leukemia • Oncology • Sezary Syndrome • PAK1

JALON THERAPEUTICS RAISES NEARLY 2 MILLION EUROS TO DEVELOP A DISRUPTIVE APPROACH IN ONCOLOGY (GlobeNewswire) - "Jalon Therapeutics...announces that it has obtained nearly 2 million euros, Its first-in-class drug candidate JRT39 is in advanced preclinical development....The company now aims to raise the capital needed to finance the regulatory studies prior to future phase I/II clinical trials as well as proof of clinical concept."

Financing • Oncology